The US Food and Drug Administration granted full approval to mirvetuximab soravtansine-gynx (Elahere) for adults with folate receptor alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.? AbbVie noted in a press release that its antibody-drug conjugate is the first treatment to show a statistically significant overall survival benefit in patients with platinum-resistant ovarian c...